vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and BARRETT BUSINESS SERVICES INC (BBSI). Click either name above to swap in a different company.
BARRETT BUSINESS SERVICES INC is the larger business by last-quarter revenue ($321.1M vs $183.1M, roughly 1.8× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 5.1%, a 8.2% gap on every dollar of revenue. On growth, BARRETT BUSINESS SERVICES INC posted the faster year-over-year revenue change (5.3% vs -1.8%). BARRETT BUSINESS SERVICES INC produced more free cash flow last quarter ($70.6M vs $24.6M). Over the past eight quarters, BARRETT BUSINESS SERVICES INC's revenue compounded faster (9.9% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Barrett Firearms Manufacturing is an Australian-owned, American manufacturer of firearms and ammunition located in Christiana, Tennessee. It was founded in 1982 by Ronnie G. Barrett for the purpose of building semi-automatic rifles chambered for the .50 BMG ammunition, originally developed for and used in M2 Browning machine guns. Barrett began this work in the early 1980s, and the first working rifles were available in 1982, hence the designation M82. Barrett personally designed every part o...
AMPH vs BBSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $321.1M |
| Net Profit | $24.4M | $16.4M |
| Gross Margin | 46.8% | 21.3% |
| Operating Margin | 19.4% | 5.8% |
| Net Margin | 13.3% | 5.1% |
| Revenue YoY | -1.8% | 5.3% |
| Net Profit YoY | -35.7% | -2.4% |
| EPS (diluted) | $0.51 | $0.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $321.1M | ||
| Q3 25 | $191.8M | $318.9M | ||
| Q2 25 | $174.4M | $307.7M | ||
| Q1 25 | $170.5M | $292.6M | ||
| Q4 24 | $186.5M | $304.8M | ||
| Q3 24 | $191.2M | $294.3M | ||
| Q2 24 | $182.4M | $279.7M | ||
| Q1 24 | $171.8M | $265.8M |
| Q4 25 | $24.4M | $16.4M | ||
| Q3 25 | $17.4M | $20.6M | ||
| Q2 25 | $31.0M | $18.5M | ||
| Q1 25 | $25.3M | $-1.0M | ||
| Q4 24 | $38.0M | $16.8M | ||
| Q3 24 | $40.4M | $19.6M | ||
| Q2 24 | $37.9M | $16.7M | ||
| Q1 24 | $43.2M | $-136.0K |
| Q4 25 | 46.8% | 21.3% | ||
| Q3 25 | 51.4% | 24.1% | ||
| Q2 25 | 49.6% | 23.8% | ||
| Q1 25 | 50.0% | 14.6% | ||
| Q4 24 | 46.5% | 23.4% | ||
| Q3 24 | 53.3% | 25.3% | ||
| Q2 24 | 52.2% | 24.3% | ||
| Q1 24 | 52.4% | 14.9% |
| Q4 25 | 19.4% | 5.8% | ||
| Q3 25 | 13.2% | 7.8% | ||
| Q2 25 | 24.2% | 7.5% | ||
| Q1 25 | 21.9% | -1.4% | ||
| Q4 24 | 24.2% | 6.8% | ||
| Q3 24 | 29.8% | 8.0% | ||
| Q2 24 | 30.3% | 7.3% | ||
| Q1 24 | 27.9% | -1.8% |
| Q4 25 | 13.3% | 5.1% | ||
| Q3 25 | 9.0% | 6.5% | ||
| Q2 25 | 17.8% | 6.0% | ||
| Q1 25 | 14.8% | -0.3% | ||
| Q4 24 | 20.4% | 5.5% | ||
| Q3 24 | 21.1% | 6.7% | ||
| Q2 24 | 20.8% | 6.0% | ||
| Q1 24 | 25.1% | -0.1% |
| Q4 25 | $0.51 | $0.63 | ||
| Q3 25 | $0.37 | $0.79 | ||
| Q2 25 | $0.64 | $0.70 | ||
| Q1 25 | $0.51 | $-0.04 | ||
| Q4 24 | $0.74 | $0.63 | ||
| Q3 24 | $0.78 | $0.74 | ||
| Q2 24 | $0.73 | $0.62 | ||
| Q1 24 | $0.81 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $157.2M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $241.0M |
| Total Assets | $1.6B | $779.1M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $157.2M | ||
| Q3 25 | $276.2M | $109.8M | ||
| Q2 25 | $231.8M | $90.4M | ||
| Q1 25 | $236.9M | $99.1M | ||
| Q4 24 | $221.6M | $121.9M | ||
| Q3 24 | $250.5M | $14.4M | ||
| Q2 24 | $217.8M | $40.3M | ||
| Q1 24 | $289.6M | $51.3M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $241.0M | ||
| Q3 25 | $776.7M | $240.1M | ||
| Q2 25 | $757.5M | $225.8M | ||
| Q1 25 | $751.3M | $213.4M | ||
| Q4 24 | $732.3M | $221.4M | ||
| Q3 24 | $727.7M | $215.4M | ||
| Q2 24 | $713.3M | $199.0M | ||
| Q1 24 | $672.4M | $189.6M |
| Q4 25 | $1.6B | $779.1M | ||
| Q3 25 | $1.7B | $777.9M | ||
| Q2 25 | $1.6B | $713.6M | ||
| Q1 25 | $1.6B | $778.6M | ||
| Q4 24 | $1.6B | $745.5M | ||
| Q3 24 | $1.5B | $725.8M | ||
| Q2 24 | $1.5B | $688.6M | ||
| Q1 24 | $1.6B | $747.8M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $76.1M |
| Free Cash FlowOCF − Capex | $24.6M | $70.6M |
| FCF MarginFCF / Revenue | 13.4% | 22.0% |
| Capex IntensityCapex / Revenue | 4.5% | 1.7% |
| Cash ConversionOCF / Net Profit | 1.35× | 4.64× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $47.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $76.1M | ||
| Q3 25 | $52.6M | $38.4M | ||
| Q2 25 | $35.6M | $-53.8M | ||
| Q1 25 | $35.1M | $5.2M | ||
| Q4 24 | $29.0M | $53.4M | ||
| Q3 24 | $60.0M | $-935.0K | ||
| Q2 24 | $69.1M | $-51.3M | ||
| Q1 24 | $55.3M | $9.0M |
| Q4 25 | $24.6M | $70.6M | ||
| Q3 25 | $47.2M | $34.1M | ||
| Q2 25 | $25.0M | $-58.2M | ||
| Q1 25 | $24.4M | $697.0K | ||
| Q4 24 | $16.6M | $50.2M | ||
| Q3 24 | $46.2M | $-4.2M | ||
| Q2 24 | $63.1M | $-56.3M | ||
| Q1 24 | $46.5M | $6.2M |
| Q4 25 | 13.4% | 22.0% | ||
| Q3 25 | 24.6% | 10.7% | ||
| Q2 25 | 14.3% | -18.9% | ||
| Q1 25 | 14.3% | 0.2% | ||
| Q4 24 | 8.9% | 16.5% | ||
| Q3 24 | 24.1% | -1.4% | ||
| Q2 24 | 34.6% | -20.1% | ||
| Q1 24 | 27.1% | 2.3% |
| Q4 25 | 4.5% | 1.7% | ||
| Q3 25 | 2.8% | 1.4% | ||
| Q2 25 | 6.1% | 1.4% | ||
| Q1 25 | 6.3% | 1.5% | ||
| Q4 24 | 6.7% | 1.0% | ||
| Q3 24 | 7.2% | 1.1% | ||
| Q2 24 | 3.3% | 1.8% | ||
| Q1 24 | 5.1% | 1.0% |
| Q4 25 | 1.35× | 4.64× | ||
| Q3 25 | 3.03× | 1.86× | ||
| Q2 25 | 1.15× | -2.92× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | 3.18× | ||
| Q3 24 | 1.48× | -0.05× | ||
| Q2 24 | 1.82× | -3.07× | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
BBSI
| Professional Employer Services | $303.6M | 95% |
| Staffing Services | $17.6M | 5% |
